Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024;31(23):3631-3652.
doi: 10.2174/0929867330666230516123028.

Microarray-based Detection of Critical Overexpressed Genes in the Progression of Hepatic Fibrosis in Non-alcoholic Fatty Liver Disease: A Protein-protein Interaction Network Analysis

Affiliations

Microarray-based Detection of Critical Overexpressed Genes in the Progression of Hepatic Fibrosis in Non-alcoholic Fatty Liver Disease: A Protein-protein Interaction Network Analysis

Ali Mahmoudi et al. Curr Med Chem. 2024.

Abstract

Background: Non-alcoholic fatty liver disease (NAFLD) is a prevalent cause of chronic liver disease and encompasses a broad spectrum of disorders, including simple steatosis, steatohepatitis, fibrosis, cirrhosis, and liver cancer. However, due to the global epidemic of NAFLD, where invasive liver biopsy is the gold standard for diagnosis, it is necessary to identify a more practical method for early NAFLD diagnosis with useful therapeutic targets; as such, molecular biomarkers could most readily serve these aims. To this end, we explored the hub genes and biological pathways in fibrosis progression in NAFLD patients.

Methods: Raw data from microarray chips with GEO accession GSE49541 were downloaded from the Gene Expression Omnibus database, and the R package (Affy and Limma) was applied to investigate differentially expressed genes (DEGs) involved in the progress of low- (mild 0-1 fibrosis score) to high- (severe 3-4 fibrosis score) fibrosis stage NAFLD patients. Subsequently, significant DEGs with pathway enrichment were analyzed, including gene ontology (GO), KEGG and Wikipathway. In order to then explore critical genes, the protein-protein interaction network (PPI) was established and visualized using the STRING database, with further analysis undertaken using Cytoscape and Gephi software. Survival analysis was undertaken to determine the overall survival of the hub genes in the progression of NAFLD to hepatocellular carcinoma.

Results: A total of 311 significant genes were identified, with an expression of 278 being upregulated and 33 downregulated in the high vs. low group. Gene functional enrichment analysis of these significant genes demonstrated major involvement in extracellular matrix (ECM)-receptor interaction, protein digestion and absorption, and the AGE-RAGE signaling pathway. The PPI network was constructed with 196 nodes and 572 edges with PPI enrichment using a p-value < 1.0 e-16. Based on this cut-off, we identified 12 genes with the highest score in four centralities: Degree, Betweenness, Closeness, and Eigenvector. Those twelve hub genes were CD34, THY1, CFTR, COL3A1, COL1A1, COL1A2, SPP1, THBS1, THBS2, LUM, VCAN, and VWF. Four of these hub genes, namely CD34, VWF, SPP1, and VCAN, showed significant association with the development of hepatocellular carcinoma.

Conclusion: This PPI network analysis of DEGs identified critical hub genes involved in the progression of fibrosis and the biological pathways through which they exert their effects in NAFLD patients. Those 12 genes offer an excellent opportunity for further focused research to determine potential targets for therapeutic applications.

Keywords: GO ontology; Gene expression; KEGG enrichment; PPI network; Wikipathway; hub genes; survival analysis..

PubMed Disclaimer

Similar articles

Cited by

References

    1. Al-Qarni R.; Iqbal M.; Al-Otaibi M.; Al-Saif F.; Alfadda A.A.; Alkhalidi H.; Bamehriz F.; Hassanain M.; Validating candidate biomarkers for different stages of non-alcoholic fatty liver disease. Medicine 2020,99(36),e21463 - DOI - PubMed
    1. Pellicano A.J.; Spahn K.; Zhou P.; Goldberg I.D.; Narayan P.; Collagen characterization in a model of nonalcoholic steatohepatitis with fibrosis; a call for development of targeted therapeutics. Molecules 2021,26(11),3316 - DOI - PubMed
    1. Romualdo G.R.; Da Silva T.C.; Landi M.F.; Morais J.Á.; Barbisan L.F.; Vinken M.; Oliveira C.P.; Cogliati B.; Sorafenib reduces steatosis-induced fibrogenesis in a human co-culture model of non-alcoholic fatty liver disease. Environ Toxicol 2021,36(2),168-176 - DOI - PubMed
    1. Zeng Y.; He H.; An Z.; Advance of serum biomarkers and combined diagnostic panels in nonalcoholic fatty liver disease. Dis Markers 2022,2022,1-12 - DOI - PubMed
    1. Sahebkar A.; Sancho E.; Abelló D.; Camps J.; Joven J.; Novel circulating biomarkers for non-alcoholic fatty liver disease: A systematic review. J Cell Physiol 2018,233(2),849-855 - DOI - PubMed

MeSH terms